Dexamethasone reduces side population fraction through downregulation of ABCG2 transporter in MCF-7 breast cancer cells

Kim,Jong  Bin; Hwang,Sung  Eun; Yoon,Sang‑Pil

doi:10.3892/mmr.2017.6566

Dexamethasone reduces side population fraction through downregulation of ABCG2 transporter in MCF-7 breast cancer cells

Authors:
- Jong Bin Kim
- Sung Eun Hwang
- Sang‑Pil Yoon
View Affiliations

Affiliations: Ewha Institute of Convergence Medicine, Ewha Womans University Mokdong Hospital, Ewha Womans University, Seoul 03080, Republic of Korea, Department of Surgery, College of Medicine, Graduate School, Chungnam National University, Daejeon 35015, Republic of Korea, Department of Anatomy, School of Medicine, Jeju National University, Jeju 63243, Republic of Korea
Published online on: May 10, 2017 https://doi.org/10.3892/mmr.2017.6566
Pages: 453-458

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Side population (SP) cells represent a rare population among breast cancer cells. SP cells have been reported to act as cancer stem‑like cells, and to participate in the development of multidrug resistance via modulating the expression of ATP-binding cassette subfamily G member 2 (ABCG2). Dexamethasone is a corticosteroid drug that has been used as an adjuvant treatment to enhance the efficacy of chemotherapeutic agents; however, its effects in breast cancer have yet to be thoroughly investigated. In the present study, the effects of dexamethasone were investigated using the human MCF‑7 breast cancer cell line, and SPs were examined in detail. Cellular proliferation, SP fractions and ABCG2 expression were examined following treatment of MCF‑7 cells with dexamethasone. Dexamethasone was revealed to cause a dose‑ and time‑dependent decrease in cancer cell proliferation, and it also decreased the size of the SP fraction of MCF‑7 cells and the expression of the ABCG2 transporter. The effects of dexamethasone on cellular proliferation, SP fraction and ABCG2 expression were abolished following the administration of the glucocorticoid antagonist RU486. These results suggested that dexamethasone may target breast cancer cell SPs and thus increase the sensitivity of tumor cells to chemotherapy. Therefore, it may be hypothesized that dexamethasone can be used as a chemosensitizer in the adjuvant treatment of patients with breast cancer.

View Figures

View References

1	Boyd C and Náray-Fejes-Tóth A: Steroid-mediated regulation of the epithelial sodium channel subunits in mammary epithelial cells. Endocrinology. 148:3958–3967. 2007. View Article : Google Scholar : PubMed/NCBI
2	Gong H, Jarzynka MJ, Cole TJ, Le JH, Wada T, Zhang B, Gao J, Song WC, DeFranco DB, Cheng SY and Xie W: Glucocorticoids antagonize estrogens by glucocorticoid receptor-mediated activation of estrogen sulfotransferase. Cancer Res. 68:7386–7393. 2008. View Article : Google Scholar : PubMed/NCBI
3	Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M and Hofbauer LC: Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem. 108:106–116. 2009. View Article : Google Scholar : PubMed/NCBI
4	Buxant F, Kindt N, Laurent G, Noël JC and Saussez S: Antiproliferative effect of dexamethasone in the MCF-7 breast cancer cell line. Mol Med Rep. 12:4051–4054. 2015.PubMed/NCBI
5	Machuca C, Mendoza-Milla C, Córdova E, Mejía S, Covarrubias L, Ventura J and Zentella A: Dexamethasone protection from TNF-alpha-induced cell death in MCF-7 cells requires NF-kappaB and is independent from AKT. BMC Cell Biol. 7:92006. View Article : Google Scholar : PubMed/NCBI
6	Khan S, Lopez-Dee Z, Kumar R and Ling J: Activation of NFkB is a novel mechanism of pro-survival activity of glucocorticoids in breast cancer cells. Cancer Lett. 337:90–95. 2013. View Article : Google Scholar : PubMed/NCBI
7	Wang H, Wang Y, Rayburn ER, Hill DL, Rinehar JJ and Zhang R: Dexamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol. 30:947–953. 2007.PubMed/NCBI
8	Pang D, Kocherginsky M, Krausz T, Kim SY and Conzen SD: Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 5:933–940. 2006. View Article : Google Scholar : PubMed/NCBI
9	Honorat M, Mesnier A, Di Pietro A, Lin V, Cohen P, Dumontet C and Payen L: Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem Biophys Res Commun. 375:308–314. 2008. View Article : Google Scholar : PubMed/NCBI
10	Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kim JB, Ko E, Han W, Shin I, Park SY and Noh DY: Berberine diminishes the side population and ABCG2 transporter expression in MCF-7 breast cancer cells. Planta Med. 74:1693–1700. 2008. View Article : Google Scholar : PubMed/NCBI
12	Phillips TM, McBride WH and Pajonk F: The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006. View Article : Google Scholar : PubMed/NCBI
13	Xu Y, He Z, Zhu H, Chen X, Li J, Zhang H, Pan X and Hu Y: Murine fertilized ovum, blastomere and morula cells lacking SP phenotype. Sci China C Life Sci. 50:762–765. 2007. View Article : Google Scholar : PubMed/NCBI
14	Scharenberg CW, Harkey MA and Torok-Storb B: The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood. 99:507–512. 2002. View Article : Google Scholar : PubMed/NCBI
15	Dieterlen-Lièvre F: Lineage-switching by pluripotent cells derived from adults. J Soc Biol. 195:39–46. 2001.(In French). View Article : Google Scholar : PubMed/NCBI
16	Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K and Tang DG: Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65:6207–6219. 2005. View Article : Google Scholar : PubMed/NCBI
17	Burkert J, Otto W and Wright N: Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol. 214:564–573. 2008. View Article : Google Scholar : PubMed/NCBI
18	Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, et al: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 105:2445–2450. 2008. View Article : Google Scholar : PubMed/NCBI
19	Ho MM, Ng AV, Lam S and Hung JY: Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67:4827–4833. 2007. View Article : Google Scholar : PubMed/NCBI
20	Yin L, Castagnino P and Assoian RK: ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res. 68:800–807. 2008. View Article : Google Scholar : PubMed/NCBI
21	Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet J Jr, Badve S and Nakshatri H: CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar : PubMed/NCBI
22	Pavek P, Merino G, Wagenaar E, Bolscher E, Novotna M, Jonker JW and Schinkel AH: Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J Pharmacol Exp Ther. 312:144–152. 2005. View Article : Google Scholar : PubMed/NCBI
23	Elahian F, Kalalinia F and Behravan J: Dexamethasone downregulates BCRP mRNA and protein expression in breast cancer cell lines. Oncol Res. 18:9–15. 2009. View Article : Google Scholar : PubMed/NCBI
24	Elahian F, Kalalinia F and Behravan J: Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 33:113–119. 2010. View Article : Google Scholar : PubMed/NCBI
25	Fujii Y and Nakayama M: Reduction of postoperative nausea and vomiting and analgesic requirement with dexamethasone in women undergoing general anesthesia for mastectomy. Breast J. 13:564–567. 2007. View Article : Google Scholar : PubMed/NCBI
26	Igarashi H, Medina KL, Yokota T, Rossi MI, Sakaguchi N, Comp PC and Kincade PW: Early lymphoid progenitors in mouse and man are highly sensitive to glucocorticoids. Int Immunol. 17:501–511. 2005. View Article : Google Scholar : PubMed/NCBI
27	Srivastava AS, Kaushal S, Mishra R, Lane TA and Carrier E: Dexamethasone facilitates erythropoiesis in murine embryonic stem cells differentiating into hematopoietic cells in vitro. Biochem Biophys Res Commun. 346:508–516. 2006. View Article : Google Scholar : PubMed/NCBI
28	Choi YH, Ko SH, Kim SJ, Lee WY, Park JH and Lee JM: Induction of cell death by photodynamic therapy with a new synthetic photosensitizer DH-I-180-3 in undifferentiated and differentiated 3T3-L1 cells. Biochem Biophys Res Commun. 337:1059–1064. 2004. View Article : Google Scholar
29	Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ and Barlogie B: Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: A southwest oncology group trial (S0204). J Clin Oncol. 27:3510–3517. 2009. View Article : Google Scholar : PubMed/NCBI
30	Ahmed S, Johnson CS, Reuger RM and Trump DL: Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol. 168:756–761. 2002. View Article : Google Scholar : PubMed/NCBI